Literature DB >> 30468278

Bufalin induces protective autophagy by Cbl-b regulating mTOR and ERK signaling pathways in gastric cancer cells.

Hai-Yan Qi1,2, Xiu-Juan Qu1, Jing Liu1, Ke-Zuo Hou1, Yi-Bo Fan1, Xiao-Fang Che1, Yun-Peng Liu1.   

Abstract

Bufalin, a natural small-molecule compound derived from the traditional Chinese medicine Chan su, has shown promising anti-cancer effects against a broad variety of cancer cells through different mechanisms. It has been reported to induce autophagy in gastric cancer cells. However, the molecular mechanism involved is not fully elucidated. In the present study, we aimed to investigate the molecular mechanism by which bufalin induce autophagy in human gastric cancer cells. We found that bufalin induced apoptosis and autophagy in gastric cancer cells, and autophagy prevented human gastric cancer cells from undergoing apoptosis. Bufalin treatment changed the expression of autophagy-related proteins. Moreover, phosphorylated Akt, mTOR, and p70S6K were all significantly decreased, while phosphorylated ERK1/2 was increased by bufalin. Pretreatment of MGC803 cells with the ERK1/2-specific inhibitor PD98059 led to the down-regulation of LC3 II. Further study showed that Cbl-b positively regulated autophagy by suppressing mTOR and enhancing ERK1/2 activation. Therefore, our data provide evidence that bufalin induces autophagy in MGC803 cells via both Akt/mTOR/p70S6K and ERK signaling pathways, and Cbl-b-mediated suppression of mTOR and activation of ERK1/2 might play an important role.
© 2018 International Federation for Cell Biology.

Entities:  

Keywords:  Atg; LC3; apoptosis; autophagy; bufalin; cancer therapy

Mesh:

Substances:

Year:  2019        PMID: 30468278     DOI: 10.1002/cbin.11076

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  5 in total

1.  Molecular imaging of the kinetics of hyperactivated ERK1/2-mediated autophagy during acquirement of chemoresistance.

Authors:  Aniketh Bishnu; Pratham Phadte; Ajit Dhadve; Asmita Sakpal; Bharat Rekhi; Pritha Ray
Journal:  Cell Death Dis       Date:  2021-02-08       Impact factor: 8.469

2.  Therapeutic Targets of Bufalin on Renal Carcinoma and Mechanisms: Experimental Validation of Network Pharmacology Analysis.

Authors:  Lei Zhang; Yi-Ming Pan; Lu-Yao Wang; Wan-Zhu Zhao; Shao-Cheng Yang; Xue-Fang Sun; Xin Guan; Bing Yan
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-28       Impact factor: 2.629

Review 3.  Chemistry and the Potential Antiviral, Anticancer, and Anti-Inflammatory Activities of Cardiotonic Steroids Derived from Toads.

Authors:  Hesham R El-Seedi; Nermeen Yosri; Bishoy El-Aarag; Shaymaa H Mahmoud; Ahmed Zayed; Ming Du; Aamer Saeed; Syed G Musharraf; Islam M El-Garawani; Mohamed R Habib; Haroon Elrasheid Tahir; Momtaz M Hegab; Xiaobo Zou; Zhiming Guo; Thomas Efferth; Shaden A M Khalifa
Journal:  Molecules       Date:  2022-10-05       Impact factor: 4.927

4.  Vitexin suppresses renal cell carcinoma by regulating mTOR pathways.

Authors:  Yuhong Li; Qinghai Sun; Hui Li; Bin Yang; Meng Wang
Journal:  Transl Androl Urol       Date:  2020-08

5.  C₁₈H₁₇NO₆ Inhibits Invasion and Migration of Human MNNG Osteosarcoma Cells via the PI3K/AKT Signaling Pathway.

Authors:  Qianqian Qu; Zhongshun He; Yulei Jiang; Di Lu; Xiaolin Long; Yu Ding; Biao Xu; Xiaoqiong He
Journal:  Med Sci Monit       Date:  2019-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.